Showing 2,621 - 2,640 results of 2,897 for search '"stem cells"', query time: 0.07s Refine Results
  1. 2621
  2. 2622

    Tracheobronchial Manifestations of Aspergillus Infections by Rafal Krenke, Elzbieta M. Grabczak

    Published 2011-01-01
    “…Thus, invasive or potentially invasive Aspergillus airway diseases are discussed separately in three groups of patients: (1) lung transplant recipients, (2) highly immunocompromised patients with hematologic malignancies and/or patients undergoing hematopoietic stem cell transplantation, and (3) the remaining, less severely immunocompromised patients or even immunocompetent subjects.…”
    Get full text
    Article
  3. 2623

    Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD by Philip T. Sobash, Achuta K. Guddati, Vamsi Kota

    Published 2020-01-01
    “…We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups. …”
    Get full text
    Article
  4. 2624
  5. 2625

    Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration by Nan Jiang, Cheng Wu, Xunrong Zhou, Guanghua Zhai, Jian Wu

    Published 2021-01-01
    “…In addition, such as neuromodulatory proteins, proimmune ligands, gene therapy, stem cell therapy, and the current cutting-edge low-energy shock wave therapy have shown advantages in basic research and limited clinical studies. …”
    Get full text
    Article
  6. 2626

    Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas by Marco Gunnellini, Lorenzo Falchi

    Published 2012-01-01
    “…Alternative chemoimmunotherapy regimens are often used as salvage strategy and stem cell transplant remains an option for selected patients. …”
    Get full text
    Article
  7. 2627

    Inflammatory Serum Biomarkers in Colorectal Cancer in Kazakhstan Population by L. Akhmaltdinova, V. Sirota, V. Zhumaliyeva, D. Babenko, I. Kadyrova, Z. Tauesheva, D. Taizhanova, A. Ibraeva, M. Maratkyzy, A. Turmukhambetova

    Published 2020-01-01
    “…The following biomarkers were included in the study panel: stem cell factor (SCF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF2), interleukin 6 (IL6), interleukin 8 (IL8), macrophage migration inhibitory factor (MIF), soluble Fas (SFAS), soluble Fas ligand (sFASL), transforming growth factor β (TGF), tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and programmed death ligand 1 (PD-L1). …”
    Get full text
    Article
  8. 2628

    Nanobody-thioesterase chimeras to specifically target protein palmitoylation by Chien-Wen Kuo, Caglar Gök, Hannah Fulton, Eleanor Dickson-Murray, Samuel Adu, Emily K. Gallen, Sheon Mary, Alan D. Robertson, Fiona Jordan, Emma Dunning, William Mullen, Godfrey L. Smith, William Fuller

    Published 2025-02-01
    “…Using a thioesterase fused to a nanobody directed against the Ca(v)1.2 beta subunit we reduce palmitoylation of the Ca(v)1.2 alpha subunit, modifying the channel’s voltage dependence and arrhythmia susceptibility in stem cell derived cardiac myocytes. We conclude that nanobody enzyme chimeras represent an approach to specifically manipulate PTMs, with applications in both the laboratory and the clinic.…”
    Get full text
    Article
  9. 2629

    Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions by Tiantian Wang, Dong Zhou, Zhen Hong

    Published 2025-01-01
    “…This review discusses the muscle microenvironment's changes contributing to these conditions, recent therapeutic approaches like lifestyle modifications, small molecules, and nutritional interventions, and emerging strategies such as gene editing, stem cell therapy, and gut microbiome modulation. We also address the challenges and opportunities of multimodal interventions, aiming to provide insights into the pathogenesis and molecular mechanisms of sarcopenia and cachexia, ultimately aiding in innovative strategy development and improved treatments.…”
    Get full text
    Article
  10. 2630

    Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion by Mireille Crampe, Laura Kearney, David O’Brien, C. Larry Bacon, Derville O’Shea, Stephen E. Langabeer

    Published 2019-01-01
    “…Molecular monitoring reflected the disease response from diagnosis through allogeneic stem cell transplantation which resulted in undetectable e13a3 BCR-ABL1 transcripts. …”
    Get full text
    Article
  11. 2631

    HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature by Michael J. Grant, Mitchell E. Horwitz

    Published 2018-01-01
    “…Over 30 cases of hematopoietic stem cell transplant-related GAVE (HSCT-GAVE) have been reported in the literature to date and there are likely many more that go undiagnosed or are attributed to another cause of upper gastrointestinal bleeding. …”
    Get full text
    Article
  12. 2632

    Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing by Margeaux Hodgson-Garms, Matthew J. Moore, Mikaël M. Martino, Kilian Kelly, Jessica E. Frith

    Published 2025-02-01
    “…This study analysed the secretomes of bone-marrow (BM.MSCs), umbilical-cord (UC.MSCs), adipose-tissue (AT.MSCs) and clinical/commercial-grade induced pluripotent stem cell-derived MSCs (iMSCs), under resting and inflammatory licenced conditions. iMSCs recapitulated the inflammatory licensing process, validating their comparability to tissue-derived MSCs. …”
    Get full text
    Article
  13. 2633

    Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis by Hanxiao Sun, Yang Zou, Zhengtai Chen, Yan He, Kai Ye, Huan Liu, Lihong Qiu, Yufan Zhang, Yuexue Mai, Xinghong Chen, Zhengwei Mao, Wei Wang, Chenggang Yi

    Published 2025-01-01
    “…A Cu‐chelator (Clioquinol, CQ) polydopamine (PDA)‐modified stem cell exosome loaded with siRNA‐FDX1, named EXOsiFDX1‐PDA@CQ, is designed to efficiently inhibit the two cuproptosis pathways. …”
    Get full text
    Article
  14. 2634

    Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients by Edward Kim, Alina Adeel, Adel Bozorgzadeh, Shinya Amano, Curtis T. Barry, Jennifer S. Daly, Deepika Devuni, Zendee Elaba, Laura Houk, Paulo N. Martins, Babak Movahedi, Muthalagu Ramanathan, Nicole M. Theodoropoulos

    Published 2021-01-01
    “…We report on two patients who developed aGvHD after liver transplantation who were treated with ruxolitinib, a novel Janus kinase 1/2 (JAK) inhibitor that has been shown to improve outcomes in steroid refractory cases of aGvHD after allogenic hematopoietic stem cell transplantation. We reviewed the literature to discuss various therapeutic options currently available for aGvHD after liver transplantation.…”
    Get full text
    Article
  15. 2635

    Advancements in Antioxidant-Based Therapeutics for Spinal Cord Injury: A Critical Review of Strategies and Combination Approaches by Yang-Jin Shen, Yin-Cheng Huang, Yi-Chuan Cheng

    Published 2024-12-01
    “…This review provides a comprehensive and critical evaluation of recent advancements in antioxidant-based therapeutic strategies for SCI, including natural compounds, RNA-based therapies, stem cell interventions, and biomaterial applications. …”
    Get full text
    Article
  16. 2636

    Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia by Ronak H. Mistry, Elizabeth O. Hexner, James K. Mangan

    Published 2019-01-01
    “…Current standard of care for T-PLL is with alemtuzumab, followed by allogeneic or autologous stem cell transplant. Little is found in the literature about alternative donor transplantation in T-PLL. …”
    Get full text
    Article
  17. 2637

    Critical Aspects of Clinical Trial Design for Novel Cell and Gene Therapies by Zinovia Kefalopoulou, Iciar Aviles-Olmos, Thomas Foltynie

    Published 2011-01-01
    “…Beyond the provision of symptomatic efficacy and safety data, it also remains to be identified whether the possibilities offered by stem cell and gene therapy technological advances might translate to meaningful neuroprotection and/or disease-modifying effects or alleviate the nonmotor aspects of PD and thus offer additional benefits beyond those achieved through conventional pharmacotherapy or deep brain stimulation (DBS).…”
    Get full text
    Article
  18. 2638
  19. 2639
  20. 2640

    Presumed Glenoid SLAP Tear in an Adolescent Football Player Belied the Presence of a Coracoid Growth Plate Fracture: A Diagnostic Conundrum by John G. Skedros, J. Hunter Marshall, John T. Cronin

    Published 2022-01-01
    “…Hoping to expedite his healing with platelet or stem cell injections, the parents sought an opinion from another physician who obtained a right shoulder MRI with intra-articular contrast. …”
    Get full text
    Article